More Than 5 Million Smokers Successfully Smoke-Free Since Therapeutic Nicotine Made Available Over-the-Counter A Decade Ago

-Effective Policy Changes Worldwide Reinforce Need for Safe, Effective and

Accessible Quit Methods-

Jul 12, 2006, 01:00 ET from GlaxoSmithKline Consumer Healthcare

    WASHINGTON, July 12 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer
 Healthcare is marking the 10th anniversary of when therapeutic nicotine
 (TN) products became available over-the-counter (OTC) at the 13th World
 Conference on Tobacco OR Health (WCTOH). GSK's therapeutic nicotine
 products have helped more than five million smokers around the world
 successfully quit using safe and effective stop-smoking aids. Yet, there is
 a significant need to encourage and educate the more than 1.3 billion
 current smokers around the world on how to quit successfully. Shifts in
 public policy like smoke-free laws and cigarette tax increases are
 encouraging more and more smokers to attempt quitting. It is important that
 those smokers have access to counseling, behavioral support programs, and
 FDA-approved safe and effective stop-smoking products. At the conference,
 GSK will highlight the latest support resources available to smokers.
     "Over the past decade, GSK has made tremendous progress by helping
 millions of smokers quit successfully and live longer tobacco-free lives,"
 said Katie Kemper, vice president, GSK Global Smoking Control. "But our job
 is far from over. Smokers must understand that there is no magic pill.
 Smokers and health care professionals need to know that successful quit
 attempts require breaking the addiction to nicotine and modifying
     International guidelines from the United States, United Kingdom and the
 World Health Organization (WHO) recommend TN as a first-line treatment for
 smoking addiction. Quitters using therapeutic nicotine can double their
 chances of success versus quitting without help. Therapeutic nicotine
 products like Nicorette(R) gum, NicoDerm(R) CQ(R) patch and Commit(R)
 lozenge, are available in more than 35,000 retail outlets in the United
 States and under the NiQuitin brand name in other countries. These stop
 smoking aids are designed specifically to break the daily addiction cycle
 by offering a gradual, controlled delivery of nicotine to the body, helping
 to relieve cravings and withdrawal symptoms.
     "Many smokers wrongly believe they can simply put down their cigarettes
 and walk away forever," said Saul Shiffman, PhD, world-renowned researcher
 and professor in the departments of psychology and pharmaceutical science
 at the University of Pittsburgh. "What smokers don't realize is while the
 body clears nicotine relatively quickly the effects of nicotine can last
 for months. Therapeutic nicotine helps safely reduce cravings so a smoker
 can wean himself off nicotine gradually, allowing him to focus on changing
 his behavior."
     Nicotine Addiction + Habit Change
     Research shows that one-third of all quit attempts fail within 48
 hours. Nicotine withdrawal will lead to desperate cravings that are hard to
 overcome with willpower alone. Therapeutic nicotine releases temporary,
 controlled low doses of nicotine in a steady stream that ends gradually and
 it helps to relieve cravings by teaching the brain to live with less
 nicotine and then eventually no nicotine.
     Tobacco-delivered nicotine re-programs and trains their brain to
 connect daily routines with familiar cravings to sustain certain levels of
 nicotine. Everyday activities trigger the urge to smoke, such as drinking
 coffee in the morning, talking on the phone, taking a break at work, and
 driving. During these times, cravings for a cigarette are actually the
 brain looking for an intake of nicotine. Therapeutic nicotine relieves
 these intense cravings, as it gives the brain exactly what it needs. It
 reduces intense cravings and withdrawal symptoms, helping quitters more
 easily cope.
     Safety and Efficacy of Therapeutic Nicotine
     Therapeutic nicotine is extensively proven to reduce and often
 eliminate cravings during quitting, allowing smokers to focus on behavior
 change. More than 110 studies involving tens of thousands of participants
 have demonstrated the safety of therapeutic nicotine, even in populations
 with specific health conditions, such as diabetes, high blood pressure,
 lung disease, and existing heart disease.
     Additional Smoking Cessation Resources
     Because quitting cigarettes also requires behavior change, GSK Consumer
 Healthcare offers smokers a variety of customized resources to help smokers
 and non-smokers understand and address smoking cessation and address habits
 formed from smoking. GSK also actively supports government policies which
 are proven to motivate smokers to quit, such as comprehensive clean indoor
 air legislation and other measures recommended by the Framework Convention
 on Tobacco Control.
     Committed Quitters(R)
     Committed Quitters is the only free, tailored Web-based behavioral
 support program that has been proven to increase a smoker's chances of
 quitting. This program is available as Click2Quit in the UK. Participants
 receive a customized smoking cessation plan after completing an online
 questionnaire that gathers information about their habits, behaviors, and
 motivations for smoking and quitting. The program provides coping
 strategies, advice, and incentives to stay smoke-free, and has been
 evaluated in a randomized controlled clinical trial and shown to increase a
 quitter's chances by almost 30 percent. For more information, visit .
     Phone Counseling
     GSK offers smoking cessation counselors to counsel patients five days a
 week by calling 1-877-NO ASHES in the U.S.
     About GlaxoSmithKline Consumer Healthcare
     GlaxoSmithKline Consumer Healthcare is one of the world's largest over-
 the-counter consumer healthcare products companies. Its more than 30 well-
 known brands include the leading smoking cessation products, Nicorette(R),
 NicoDerm(R) and Commit(R), NiQuitin and Nicabate, as well as many medicine
 cabinet staples such as Abreva(R), Aquafresh(R), Sensodyne(R) and Tums(R).
 GlaxoSmithKline Consumer Healthcare continues to develop innovative
 products to help all smokers find their best support system and achieve
 their goal of being cigarette free.
     About GlaxoSmithKline
     GlaxoSmithKline is one of the world's leading research-based
 pharmaceutical and consumer healthcare companies. GlaxoSmithKline is
 committed to improving the quality of human life by enabling people to do
 more, feel better and live longer.
     NOTE: GlaxoSmithKline distributes Nicorette(R) gum, Nicoderm(R) patch
 and Commit(R) lozenge in the United States. Outside of the U.S., its
 smoking cessation patch and lozenge are marketed as Nicabate(R) in
 Australia and NiQuitin(R) in other countries.
     For more information, please visit the attached link
     Contacts:    Molly Rabinovitz, GolinHarris
                  Malesia Dunn, GlaxoSmithKline Consumer Healthcare

SOURCE GlaxoSmithKline Consumer Healthcare